Business
Change of Adviser
Change of Adviser.
About this update from Genincode Plc
[{"type":"text","content":"\n\n \nGENinCode Plc\n(\"GENinCode\" or the \"Company\")\n \nChange of Adviser\n \nOxford, UK. GENinCode Plc (AIM: GENI), the predictive genetics company focused on the prevention of cardiovascular disease, is pleased to announce the appointment of Cavendish Capital Markets Limited as Nominated Adviser and Broker with immediate effect. \n \nFor more information visit www.genincode.com\n \n\n\n\n\nGENinCode Plc\n\n\nwww.genincode.com or via Walbrook PR\n\n\n\n\nMatthew Walls, CEO\n\n\n \n\n\n\n\n\n\n\n \n\n\n\n\nCavendish Capital Markets Limited (Nomad and Broker)\n\n\nTel: +44 (0)20 7397 8900\n\n\n\n\nGiles Balleny / Dan Hodkinson (Corporate Finance)\n\n\n \n\n\n\n\nNigel Birks (ECM)\nDale Bellis / Michael Johnson (Sales)\n\n\n \n\n\n\n\n\n\n\n \n\n\n\n\nWalbrook PR Limited\n\n\nTel: 020 7933 8780 or\n\n\n\n\nAnna Dunphy / Louis Ashe-Jepson / Phillip Marriage\n\n\[email protected]\n\n\n\n\n\n\n\n\n\n \nAbout GENinCode:\nGENinCode Plc is a UK based company specialising in genetic risk assessment of cardiovascular disease. Cardiovascular disease is the leading cause of death and disability worldwide.\n \nGENinCode operates business units in the UK, Europe through GENinCode S.L.U, and in the United States through GENinCode U.S. Inc.\n \nGENinCode predictive technology provides patients and physicians with globally leading preventive care and treatment strategies. GENinCode genetic tests combine clinical algorithms and bioinformatics to provide advanced patient risk assessment for coronary heart disease.\n \nAbout Cardiovascular Disease (CVD):\nHeart and circulatory disease also known as cardiovascular disease (CVD) is the leading cause of death globally, taking an estimated 17.9 million lives each year, with Coronary Heart Disease (CHD) representing the leading cause of death for men, women, and people of most racial and ethnic groups in the United States. CVD is a group of disorders of the heart and blood vessels that include coronary heart disease, cerebrovascular disease, rheumatic heart disease and other conditions. More than four out of five CVD deaths are due to heart attacks and strokes, and one third of these deaths occur prematurely in people under 70 years of age. By 2030 the global cost of CVD is set...